Welcome to Neurimmune
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases. Based on its unique RTM™ technology platform (Reverse Translational Medicine), Neurimmune pursues a novel and revolutionary approach for the development of proprietary human monoclonal antibodies as therapeutics with unique advantages that result in superior risk profiles and excellent efficacy.
Neurimmune develops human antibodies as drug candidates for CNS and other indications, with a lead program for Alzheimer's disease in Phase 1 clinical trials. Further therapeutic RTM™ derived antibodies are under development in strategic partnerships for Alzheimer's disease, Parkinson's disease and ALS.
December 6, 2013 - ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS